‘Domestic rare disease treatments’ grew as leading products

Pricey rare disease treatments have grown as leading products of domestic pharmaceutical companies.

Since they are expensive as essential drugs despite the small number of patients needing them, their sales have been significantly raised.

‘Pirespa,’ the Ildong Pharmaceutical’s only idiopathic fibroid lung treatment in Korea, has raised a chance to become a blockbuster as recording KRW 900 mi...